Skip to main
AVXL

AVXL Stock Forecast & Price Target

AVXL Analyst Ratings

Based on 2 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Anavex Life Sciences is a burgeoning biopharmaceutical company with a promising pipeline, including ANAVEX 2-73, ANAVEX 3-71, and several other compounds in various stages of development targeting Alzheimer's, Parkinson's, and rare neurodegenerative diseases. With a potential multi-indication drug, strong biomarker data, and ongoing regulatory engagement, the company's valuation is supported by a $24.0 price target and favorable long-term optionality. While an EU filing for blarcamesine was withdrawn due to negative feedback, the company aims to strengthen its disease-modifying case and precision-medicine narrative by linking clinical performance to structural biomarkers, highlighting a stronger correlation in the ABCLEAR32 population, and emphasizing long-term data showing significant time saved versus an ADNI external control.

Bears say

Anavex Life Sciences is making progress in engaging with regulators and gathering data for potential EU and U.S. approval of its drug candidates for neurodegenerative diseases. However, there is still uncertainty surrounding the EU regulatory process and the overall robustness and reproducibility of clinical data for the drugs. As the company continues to work towards a viable U.S. regulatory pathway, the ultimate success of its drug candidates will depend on the strength of their clinical data and their potential for approval in a genetically selected population. Additionally, the company may face challenges in convincing the FDA of the clinical relevance of its biomarker story.

AVXL has been analyzed by 2 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Anavex Life Sciences and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Anavex Life Sciences (AVXL) Forecast

Analysts have given AVXL a Strong Buy based on their latest research and market trends.

According to 2 analysts, AVXL has a Strong Buy consensus rating as of Aug 13, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $22, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $22, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Anavex Life Sciences (AVXL)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.